Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations
Authors:
Open Access
- 30 April 2021
- journal article
- review article
- Vol. 9
Abstract
Influenza viruses of types A and B attack 5–10% of adults and 20–30% of children, thereby causing millions of acute respiratory infections in Germany annually. A significant number of these infections are associated with complications such as pneumonia and bacterial superinfections that need hospitalization and might lead to death. In addition to vaccines, drugs were developed that might support influenza prevention and that can be used to treat influenza patients. The timely application of anti-influenza drugs can inhibit virus replication, help reduce and shorten the symptoms, and prevent death as well as virus transmission.Keywords
This publication has 61 references indexed in Scilit:
- Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trialThe Lancet Infectious Diseases, 2017
- Antiviral Medications in Seasonal and Pandemic InfluenzaDeutsches Ärzteblatt international, 2016
- Antiviral combinations for severe influenzaThe Lancet Infectious Diseases, 2014
- Facemasks and intensified hand hygiene in a German household trial during the 2009/2010 influenza A(H1N1) pandemic: adherence and tolerability in children and adultsEpidemiology and Infection, 2011
- Widespread use of neuraminidase inhibitors in JapanJournal of Infection and Chemotherapy, 2011
- Combination Chemotherapy for InfluenzaViruses, 2010
- Solution structure and functional analysis of the influenza B proton channelNature Structural & Molecular Biology, 2009
- Oseltamivir Resistance — Disabling Our Influenza DefensesNew England Journal of Medicine, 2005
- Pandemic InfluenzaThe Pediatric Infectious Disease Journal, 2004